US Isotretinoin Drugs Market Research Report Information By Form (Capsules and Injection), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

North America dominates the isotretinoin drugs market, holding the largest share. This is attributed to well-established healthcare infrastructure, supportive government regulations, a growing incidence of skin problems, genetic disorders, and cancer, along with increased research and development investments in the region. The American Academy of Dermatology (AAD) has also taken a stance on oral isotretinoin, considering both the physical and psychological impacts of acne.

Acne vulgaris affects around 85% of young adults aged 12 to 25 globally, according to the Global Burden of Disease (GBD) article. In North America, acne remains a prevalent skin issue, affecting 12% to 22% of adults in the US, according to global burden of disease surveys. The demand for acne treatment methods and pharmaceuticals has surged due to the expanding number of acne sufferers. In the US alone, over 50 million people are affected by acne annually.

An example of a significant development in the market is the launch of Absorica (isotretinoin) capsules by Teva Pharmaceutical Industries Ltd in April 2021. This marked the introduction of the first generic version for treating severe recalcitrant nodular acne in the US. The capsules, available in strengths ranging from 10 mg to 40 mg, were designed for the treatment of severe recalcitrant nodular acne in non-pregnant adults aged 12 and older with multiple inflammatory nodules measuring 5 mm or more in diameter.

Looking ahead, the North America isotretinoin drugs market is anticipated to achieve a Compound Annual Growth Rate (CAGR) of 5.06% from 2021 to 2027. This projection reflects the expected continued growth and demand for isotretinoin drugs in the region. The combination of factors such as the prevalence of skin issues, supportive regulatory environment, and ongoing research activities contributes to the positive outlook for the market in the coming years. The CAGR serves as an indicator of the potential expansion and stability of the isotretinoin drugs market in North America during the specified period.